Title
The importance of brain-derived neurotrophic factor in maintaining brain health during and after cancer treatments

Permalink
https://escholarship.org/uc/item/0833z0pc

Journal
Oncolog-Hematolog.ro, 1(42)

ISSN
2066-8716

Authors
Bota, Robert G
Bota, Daniela A

Publication Date
2018

DOI
10.26416/onhe.42.1.2018.1554

Peer reviewed
The importance of the Brain Derived Neurotropic Factor in Maintaining Brain Health during and after Cancer Treatments

Robert G. Bota, MD, MSG, DFAPA, Daniela A. Bota, MD, PhD

University of California Irvine

Abstract:

Due to the scientific advances of the last decades, cancer patient’s survival has greatly improved, and 70% of the patients now live more than five years. However, many of the cancer survivors are affected by a constellation of chronic conditions induced by the powerful cancer treatments required to achieve cancer control. The effects of chemotherapy and radiation therapy on the brain are multifactorial and involve acute and sustained insult to neuronal structures essential for normal cognitive processes as well as for emotional modulation. As result, the cognitive and emotional deficits associated with cancer treatments are pervasive. The Brain Derived Neurotrophic Factor (BDNF) is an important neuromediator that plays a significant role in developing cancer related central nervous system complications. Multiple pharmacological strategies have been proven beneficial in raising BDNF levels. Equally important, there are safe and easy to implement dietary and life-style modifications that physicians can recommend, and which can potentially stimulate BDNF synthesis and improve cancer patient’s cognitive and emotional function and quality of life.

Rezumat:

Datorita multiplelor descoperiri stiintifice din ultimele decade, supravietuirea pacientilor cu cancer a crescut semnificativ - 70% din pacientii diagnosticati cu cancer traiesc mai mult de cinci ani. Cu toate acestea, multi pacienti oncologici sunt afectati de o constelatie de conditii cronice cauzate de tratamentele folosite pentru controlul cancerului. Efectele citostaticelor si al radioterapiei pentru tumorile cerebrale sunt multiple si cauzeaza numeroase efecte adverse la nivelul structurilor neuronale necesare pentru memorie si modularea emotionala. Din acest motiv deficientele de memorie si problemele emotionale sunt observate frecvent. BDNF este un neuromodulator essential, cu un rol foarte important in dezvoltarea complicatiilor la nivelul sistemului nervos central. Interventiile farmacologice s-au demonstrat benefice pentru cresterea nivelului de BDNF. De asemenea, modificari in alimentatie si ale stilului de viata pot fi recomandate de medici si sunt relativ usor de implementat, dar au potential important de a imbunatati memoria, emotiile si calitatea vietii in pacientii cu cancer.
Due to the scientific advances of the last decades, cancer patient’s survival has greatly improved, and 70% of the patients now live more than five years (National Cancer Institute, US). However, many of the cancer survivors are affected by a constellation of chronic conditions induced by the powerful cancer treatments required to achieve cancer control. Numerous deficits – such as limb amputations, hair loss or cardiac damage – are easy to identify and to quantify. However, the burden of hidden conditions – such as cognitive and emotional deficits remains difficult to acknowledge and hard to measure using objective outcomes.

The effects of chemotherapy and radiation therapy on the brain are multifactorial and involve acute and sustained insult to neuronal structures essential for learning and memory as well as for emotional modulation. As result, the cognitive deficits associated with cancer treatments are pervasive, and 15-50% of patients reportedly develop deficits in memory, attention and executive function (Table 1). Mood disorders (depression, anxiety) are also extremely common in cancer patients, with the incidence of depression reaching more than 40% of the assessed patients and the incidence of adjustment disorder was 16%. Even more significant, the cancer patients diagnosed with a mental illness had shorter survival than the patients without psychiatric comorbidities. Quality of life, job attainment and psychosocial outcomes are also decreased in cancer survivors, with many patients reporting forgetfulness and trouble with attention in school/work.

The cognitive and emotional deficits seen in cancer patients and cancer survivors are commonly underdiagnosed due to the traditional focus on “fighting the cancer”. Historically, a variety of neuropsychiatric testing measures have been used to define cognitive abilities in cancer patients in clinical trials, but these batteries are difficult to administer and are not commonly used in the clinical practice. Computer-based neurocognitive testing is an accessible and objective measure of cognition that, when trended prospectively and longitudinally, can detect and define acute and sub-acute cognitive changes, and which might be easier to implement in oncology practices in the future. Advanced imaging can be also used in the future for diagnosing cancer-induced cognitive deficits. Studies using brain MRI techniques suggested that reduced hippocampal volume are found in chemotherapy treated colon cancer patients and brain tumor patients, respectively.

Neurotrophins are part of a class of signaling proteins essential for the development, the survival and the normal function of the nervous system. Expression of neurotrophins and their receptors occurs normally during development and in response to stimuli such as tissue injury. One of the most important neurotrophins is the brain derived neurotrophic factor (BDNF). BDNF is a growth factor protein encoded by the BDNF gene, broadly expressed in the developing and adult mammalian brain (hippocampus,
cortex, basal forebrain) \(^{25,26}\). BDNF- stimulated intracellular signaling is critical for neuronal survival, morphogenesis, and plasticity\(^{27}\). In hippocampus BDNF stimulates actin signaling in the dendritic spines and regulates dendritic spine integrity\(^{28}\), but is also required for neurogenesis\(^{29}\).

BDNF binds at least two surface receptors (TrkB and LNGFR), which activate multiple intracellular signaling cascades. TrkB (a member of the tyrosine kinase family) is encoded by NTRK2 gene, and its autophosphorylation results from ligand-specific association with BDNF. The BDNF-TrkB pathway plays an important role in short-term memory and neurogenesis. The role of LNGFR (Low-affinity nerve growth factor) is still a topic of active research.\(^{30}\)

Roles of BDNF have been implicated in brain aging\(^{31}\) as well as in the pathophysiology of brain diseases, including Alzheimer, Parkinson, and Huntington disease\(^{32}\). BDNF replacement enhances neurogenesis and sensorimotor function after stroke\(^{33}\), improves memory performance in animal models of Alzheimer disease\(^{34}\) and restores synaptic plasticity in a mouse model of native Huntington Disease\(^{35}\).

BDNF has been proven to also be involved in the pathogenesis of multiple psychiatric illnesses. Higher BDNF levels protect against depression in the elderly\(^{36}\) and BDNF serum levels can predict the development of depression in stroke patients\(^{37}\). Increased glucocorticoid production caused by stress is directly linked to decreased BDNF production\(^{38}\), which in turn further potentiate the depressive symptoms in mice\(^{39}\). An inverse relation between cortisol and BDNF was also shown in schizophrenia\(^{40}\) and post-traumatic stress disorder\(^{41}\). Lower BDNF levels are constantly found in patients with anxiety disorders\(^{42}\), and were recently recognized as a biomarker for obsessive compulsive disorder\(^{43}\).

Our published research has shown that chemotherapy treatment induces BDNF downregulation in cultured hippocampal neurons\(^{3}\). Multiple studies conducted in cancer patients have shown both that BDNF is chronically downregulated in cancer patients\(^{44}\), and that the lung cancer patients with the severely decreased BDNF levels after receiving cancer treatments are more prone to cognitive\(^{45}\) and mood impairments as well as to decreased response to chemotherapy (ESMO 2016, Yufeng Wu report). In patients with B-cell non-Hodgkin lymphoma serum BDNF levels correlate with their ability to perform accurately on cognitive tasks.\(^{45}\) These finding suggest that augmenting BDNF levels through either pharmacological or non-pharmacological approaches can be potentially beneficial for both normal brain function and response to treatment in cancer patients.

Pharmacological approaches to increase BDNF are already available and include the administration of antidepressants as the SSSRIs and of ketamine\(^{46}\). Furthermore, BDNF activation in the hippocampus is required for the biological activity of the antidepressants in the animal models\(^{46}\). New research also suggests that augmentation of BDNF levels in hippocampus can be achieved by administration of positive allosteric modulators of AMPA
receptors (ampakines)\textsuperscript{47} and that ampakine administration can potentially prevent chemotherapy-induced neuronal damage (data not published).

Interventional approaches to both increase BDNF and to treat medication-refractory depression in selected patients include transcranial magnetic stimulation (TMS)\textsuperscript{48} and electroconvulsive therapy (ECT)\textsuperscript{49}. rTMS upregulates BDNF as well as improves learning and memory in a preclinical model of vascular dementia\textsuperscript{48}, and improves motor function in the affected limb, by activating BDNF processing in stroke patients\textsuperscript{50}. A recent meta-analysis showed that ECT treatment in patients with pharmacological treatment-resistant major depressive disorder significantly increases serum/plasma level of BDNF\textsuperscript{51}. Though many of these interventions were not tested in cancer patients, they are safe and well tolerated in multiple patients’ populations and can open new areas of potential research in the immediate future.

Multiple nonpharmacologic interventions are also proven to increase BDNF and to help maintain normal cognitive and emotional functions. Environmental enrichment (the creation of a stimulating environment) is proven to increased BDNF, and in turn to increase synaptic plasticity and cognition that potentially slows or reverses cognitive impairment\textsuperscript{52,53}. Physical exercise also increase the BDNF production and has potential links to improvement in cognitive functions, in young adults\textsuperscript{54} and also in elderly population.\textsuperscript{55} Another potential approach is intermittent fasting, which directly upregulates BDNF expression in the hippocampus, and improves synapse associative interactions that might translate into improved learning and memory\textsuperscript{56}. Nutritional approaches reported to increase BDNF are numerous, and include fish oil\textsuperscript{57}, Tualang honey\textsuperscript{58}, ketogenic diet\textsuperscript{59}, cocoa\textsuperscript{59}, high flavonoid fruits and vegetables\textsuperscript{59}, soy\textsuperscript{60}, coffee\textsuperscript{61} and green tea\textsuperscript{61}.

Conclusions:

BDNF is an important neuromediator that plays a significant role in developing cancer related central nervous system complications. Pharmacological strategies to increase BDNF expression in cancer patients are still under research, though antidepressants, TMS and ECT have proven benefits in raising BDNF levels. Equally important, there are safe and easy to implement dietary and life-style modifications that physicians can recommend, and which can potentially improve cancer patient’s cognitive and emotional function and quality of life.

Bibliography:

1. Dietrich J, Monje M, Wefel J, et al: Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy. Oncologist 13:1285-95, 2008
2. Dietrich J, Han R, Yang Y, et al: CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol 5:22, 2006
3. Andres AL, Gong X, Di K, et al: Low-doses of cisplatin injure hippocampal synapses: a mechanism for 'chemo' brain? Exp Neurol 255:137-44, 2014
4. Rzeski W, Pruskil S, Macke A, et al: Anticancer agents are potent neurotoxins in vitro and in vivo. Ann Neurol 56:351-60, 2004
5. Seigers R, Schagen SB, Beerling W, et al: Long-lasting suppression of hippocampal cell proliferation and impaired cognitive performance by methotrexate in the rat. Behav Brain Res 186:168-75, 2008
6. Seigers R, Fardell JE: Neurobiological basis of chemotherapy-induced cognitive impairment: a review of rodent research. Neurosci Biobehav Rev 35:729-41, 2011
7. Fardell JE, Vardy J, Logge W, et al: Single high dose treatment with methotrexate causes long-lasting cognitive dysfunction in laboratory rodents. Pharmacol Biochem Behav 97:333-9, 2010
8. Egeland M, Guinaudie C, Du Preez A, et al: Depletion of adult neurogenesis using the chemotherapy drug temozolomide in mice induces behavioural and biological changes relevant to depression, 2017
9. Kadan-Lottick NS, Zeltzer LK, Liu Q, et al: Neurocognitive functioning in adult survivors of childhood non-central nervous system cancers. J Natl Cancer Inst 102:881-93, 2010
10. Conklin HM, Krull KR, Reddick WE, et al: Cognitive outcomes following contemporary treatment without cranial irradiation for childhood acute lymphoblastic leukemia. J Natl Cancer Inst 104:1386-95, 2012
11. Krull KR, Brinkman TM, Li C, et al: Neurocognitive outcomes decades after treatment for childhood acute lymphoblastic leukemia: a report from the St Jude lifetime cohort study. J Clin Oncol 31:4407-15, 2013
12. Vardy J, Tannock I: Cognitive function after chemotherapy in adults with solid tumours. Crit Rev Oncol Hematol 63:183-202, 2007
13. Vannorsdall TD: Cognitive Changes Related to Cancer Therapy. Med Clin North Am 101:1115-1134, 2017
14. Rooney AG, Carson A, Grant R: Depression in cerebral glioma patients: a systematic review of observational studies. J Natl Cancer Inst 103:61-76, 2011
15. Chan CM, Wan Ahmad WA, Yusof MM, et al: Effects of depression and anxiety on mortality in a mixed cancer group: a longitudinal approach using standardised diagnostic interviews. Psychooncology 24:718-25, 2015
16. Parsons HM, Harlan LC, Lynch CF, et al: Impact of cancer on work and education among adolescent and young adult cancer survivors. J Clin Oncol 30:2393-400, 2012
17. Edelstein K, Coate L, Massey C, et al: Illness intrusiveness and subjective well-being in patients with glioblastoma. J Neurooncol 126:127-35, 2016
18. Duffner PK, Armstrong FD, Chen L, et al: Neurocognitive and neuroradiologic central nervous system late effects in children treated on Pediatric Oncology Group (POG) P9605 (standard risk) and P9201 (lesser risk) acute lymphoblastic leukemia protocols (ACCL0131): a methotrexate consequence? A report from the Children's Oncology Group. J Pediatr Hematol Oncol 36:8-15, 2014
19. Langer T, Martus P, Ottensmeier H, et al: CNS late-effects after ALL therapy in childhood. Part III: neuropsychological performance in long-term
survivors of childhood ALL: impairments of concentration, attention, and memory. Med Pediatr Oncol 38:320-8, 2002

20. Lim YY, Ellis KA, Harrington K, et al: Use of the CogState Brief Battery in the assessment of Alzheimer's disease related cognitive impairment in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. J Clin Exp Neuropsychol 34:345-58, 2012

21. Schneiderman B: Hippocampal volumes smaller in chemotherapy patients. Lancet Oncol 5:202, 2004

22. Nolen SC, Lee B, Shantharam S, et al: The effects of sequential treatments on hippocampal volumes in malignant glioma patients. J Neurooncol 129:433-441, 2016

23. Huang Ej, Reichardt LF: Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 24:677-736, 2001

24. Sofroniew MV, Howe CL, Mobley WC: Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci 24:1217-81, 2001

25. Mandel AL, Ozdener H, Utermohlen V: Identification of pro- and mature brain-derived neurotrophic factor in human saliva. Arch Oral Biol 54:689-95, 2009

26. Wetmore C, Ernfors P, Persson H, et al: Localization of brain-derived neurotrophic factor mRNA to neurons in the brain by in situ hybridization. Exp Neurol 109:141-52, 1990

27. Lipsky RH, Marini AM: Brain-derived neurotrophic factor mRNA and behavior-related plasticity. Ann N Y Acad Sci 1122:130-43, 2007

28. An JJ, Gharami K, Liao GY, et al: Distinct role of long 3' UTR BDNF mRNA in spine morphology and synaptic plasticity in hippocampal neurons. Cell 134:175-87, 2008

29. Lee J, Duan W, Mattson MP: Evidence that brain-derived neurotrophic factor is required for basal neurogenesis and mediates, in part, the enhancement of neurogenesis by dietary restriction in the hippocampus of adult mice. J Neurochem 82:1367-75, 2002

30. Bartkowska K, Paquin A, Gauthier AS, et al: Trk signaling regulates neural precursor cell proliferation and differentiation during cortical development. Development 134:4369-80, 2007

31. Kirk IE, Destiny LM, Kathryn AR: The Aging Hippocampus: Interactions between Exercise, Depression, and BDNF. The Neuroscientist 18:82-97, 2011

32. Mattson MP: Glutamate and neurotrophic factors in neuronal plasticity and disease. Ann N Y Acad Sci 1144:97-112, 2008

33. Schabitz WR, Steigleder T, Cooper-Kuhn CM, et al: Intravenous brain-derived neurotrophic factor enhances poststroke sensorimotor recovery and stimulates neurogenesis. Stroke 38:2165-72, 2007

34. Blurton-Jones M, Kitazawa M, Martinez-Coria H, et al: Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci U S A 106:13594-9, 2009

35. Lynch G, Kramar EA, Rex CS, et al: Brain-derived neurotrophic factor restores synaptic plasticity in a knock-in mouse model of Huntington's disease. J Neurosci 27:4424-34, 2007

36. Kanellopoulos D, Gunning FM, Morimoto SS, et al: Hippocampal Volumes and the Brain-Derived Neurotrophic Factor val66met Polymorphism in Geriatric Major Depression. The American Journal of Geriatric Psychiatry 19:13-22, 2011
37. Li J, Zhao Y-D, Zeng J-W, et al: Serum Brain-derived neurotrophic factor levels in post-stroke depression. Journal of Affective Disorders 168:373-379, 2014
38. Naveen GH, Varambally S, Thirthalli J, et al: Serum cortisol and BDNF in patients with major depression-effect of yoga. Int Rev Psychiatry 28:273-8, 2016
39. Curto M, Martocchia A, Ferracuti S, et al: Increased Total Urinary Cortisol (tUC) and Serum Brain-derived Neurotrophic Factor (BDNF) Ratio in Alzheimer Disease (AD)-affected Patients. Alzheimer Dis Assoc Disord 31:173-176, 2017
40. Issa G, Wilson C, Terry AV, Jr., et al: An inverse relationship between cortisol and BDNF levels in schizophrenia: data from human postmortem and animal studies. Neurobiol Dis 39:327-33, 2010
41. Simsek S, Uysal C, Kaplan I, et al: BDNF and cortisol levels in children with or without post-traumatic stress disorder after sustaining sexual abuse. Psychoneuroendocrinology 56:45-51, 2015
42. Suliman S, Hemmings S, Seedat S: Brain-Derived Neurotrophic Factor (BDNF) protein levels in anxiety disorders: systematic review and meta-regression analysis. Frontiers in Integrative Neuroscience 7, 2013
43. Oliveira-Maia AJ, Castro-Rodrigues P: Brain-derived neurotrophic factor: a biomarker for obsessive-compulsive disorder? Frontiers in Neuroscience 9, 2015
44. Brum C, Stertz L, Borba E, et al: Association of serum brain-derived neurotrophic factor (BDNF) and tumor necrosis factor-alpha (TNF-alpha) with diagnosis of delirium in oncology inpatients. Rev Bras Psiquiatr 37:197-202, 2015
45. Zimmer P, Mierau A, Bloch W, et al: Post-chemotherapy cognitive impairment in patients with B-cell non-Hodgkin lymphoma: a first comprehensive approach to determine cognitive impairments after treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or rituximab and bendamustine. Leuk Lymphoma:1-6, 2014
46. Björkholm C, Monteggia LM: BDNF - a key transducer of antidepressant effects. Neuropharmacology 102:72-79, 2016
47. Lauterborn JC, Lynch G, Vanderklish P, et al: Positive Modulation of AMPA Receptors Increases Neurotrophin Expression by Hippocampal and Cortical Neurons. J. Neurosci. 20:8-21, 2000
48. Zhang N, Xing M, Wang Y, et al: Repetitive transcranial magnetic stimulation enhances spatial learning and synaptic plasticity via the VEGF and BDNF-NMDAR pathways in a rat model of vascular dementia. Neuroscience 311:284-91, 2015
49. Salehi I, Hosseini SM, Haghighi M, et al: Electroconvulsive therapy (ECT) and aerobic exercise training (AET) increased plasma BDNF and ameliorated depressive symptoms in patients suffering from major depressive disorder. J Psychiatr Res 76:1-8, 2016
50. Niimi M, Hashimoto K, Kakuda W, et al: Role of Brain-Derived Neurotrophic Factor in Beneficial Effects of Repetitive Transcranial Magnetic Stimulation for Upper Limb Hemiparesis after Stroke. PLoS One 11:e0152241, 2016
51. Rocha RB, Dondossola ER, Grande AJ, et al: Increased BDNF levels after electroconvulsive therapy in patients with major depressive disorder: A meta-analysis study. J Psychiatr Res 83:47-53, 2016
52. Gobbo OL, O'Mara SM: Impact of enriched-environment housing on brain-derived neurotrophic factor and on cognitive performance after a transient global ischemia. Behav Brain Res 152:231-41, 2004
53. Novkovic T, Mittmann T, Manahan-Vaughan D: BDNF contributes to the facilitation of hippocampal synaptic plasticity and learning enabled by environmental enrichment. Hippocampus 25:1-15, 2015
54. Hotting K, Schickert N, Kaiser J, et al: The Effects of Acute Physical Exercise on Memory, Peripheral BDNF, and Cortisol in Young Adults. Neural Plast 2016:6860573, 2016
55. Hakansson K, Ledreux A, Daffner K, et al: BDNF Responses in Healthy Older Persons to 35 Minutes of Physical Exercise, Cognitive Training, and Mindfulness: Associations with Working Memory Function. J Alzheimers Dis 55:645-657, 2017
56. Dasgupta A, Kim J, Manakkadan A, et al: Intermittent fasting promotes prolonged associative interactions during synaptic tagging/capture by altering the metaplastic properties of the CA1 hippocampal neurons. Neurobiol Learn Mem, 2017
57. Wu A, Ying Z, Gomez-Pinilla F: Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative damage, and counteract learning disability after traumatic brain injury in rats. J Neurotrauma 21:1457-67, 2004
58. Othman Z, Zakaria R, Hussain NHN, et al: Potential Role of Honey in Learning and Memory. Med Sci (Basel) 3:3-15, 2015
59. Brownlow ML, Jung SH, Moore RJ, et al: Nutritional Ketosis Affects Metabolism and Behavior in Sprague-Dawley Rats in Both Control and Chronic Stress Environments. Front Mol Neurosci 10:129, 2017
60. Katayama S, Imai R, Sugiyama H, et al: Oral administration of soy peptides suppresses cognitive decline by induction of neurotrophic factors in SAMP8 mice. J Agric Food Chem 62:3563-9, 2014
61. Sangiovanni E, Brivio P, Dell'Agli M, et al: Botanicals as Modulators of Neuroplasticity: Focus on BDNF. Neural Plasticity 2017:5965371, 2017

Table 1: Common symptoms of cancer related cognitive deficits (CRCD, chemo brain)

- Being unusually disorganized
- Confusion
- Difficulty concentrating
- Difficulty finding the right word
- Difficulty learning new skills
- Difficulty multitasking
- Fatigue
- Feeling of mental fogginess
- Short attention span
- Short-term memory problems
- Taking longer than usual to complete routine tasks
- Trouble with verbal memory, such as remembering a conversation
- Trouble with visual memory, such as recalling an image or list of words